Article | March 26, 2020

COVID-19 And Clinical Trial Regulatory Guidelines

Source: Greenphire

By Jim Murphy, CEO, Greenphire

Adaptive Trial Design and Implementation

Within the past week, both the FDA and EMA issued guidance with regards to the conduct of clinical trials during the COVID-19 pandemic.

This swift action taken by the regulatory agencies was in direct response to global concerns around assuring the safety of clinical trial participants, maintaining compliance with good clinical practice (GCP) and minimizing risks to trial integrity during this unprecedented time.

These latest regulatory guidelines permit sites, sponsors and CROs to adjust their study operations to meet changing conditions for ongoing trials, however there are conditions that must be met in order for new solutions to be considered.

Here are six steps the industry can take to support the needs of patients and sites.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader